Pseudomonas aeruginosa in dermatology.
D001769:Blood / Q000382:microbiology; D002512:Cephalothin / Q000627:therapeutic use; D002648:Child; D004473:Ecthyma / Q000473:pathology; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009254:Nafcillin / Q000627:therapeutic use; D009262:Nails / Q000473:pathology; D009582:Nitrofurantoin / Q000627:therapeutic use; D010032:Otitis Externa / Q000473:pathology; D010120:Oxytocics / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity*; D011711:Pyoderma / Q000473:pathology; D018805:Sepsis / Q000473:pathology; D012871:Skin Diseases / Q000209:etiology*; D013444:Sulfisoxazole; D014034:Toes / Q000473:pathology; D014556:Urine / Q000382:microbiology
D005839:Gentamicins; D010120:Oxytocics; D011113:Polymyxins; D009254:Nafcillin; D007612:Kanamycin; D013444:Sulfisoxazole; D009582:Nitrofurantoin; D002512:Cephalothin